title: Cardiovascular toxicity of cancer treatment.
abstract: Drugs with potential cardiac toxicity are prominent in cancer treatment, not only the old chemotherapeutic agents, but also the newer targeted drugs and biologic agents. As the long-term survival of patients with malignancies has improved and cancer turned into a chronic disease, physicians must take into account the short-term as well as long-term consequences of cancer treatment, such as chemotherapy-induced cardiotoxicity. We summarize some general characteristics and subsequently review specific antineoplastic agents that are associated with cardiac toxicity.
authors.affiliation: Heart Center, Dept of Cardiovascular Diseases, Ghent University Hospital, Belgium. Matthieu.Combes@ugent.be
authors.forename: M
authors.initials: M
authors.lastname: Combes
authors.forename: S
authors.initials: S
authors.lastname: Rottey
authors.forename: T
authors.initials: T
authors.lastname: De Backer
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D002319:Cardiovascular System / Q000187:drug effects*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008870:Microtubules / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D059003:Topoisomerase Inhibitors / Q000009:adverse effects; D050257:Tubulin Modulators / Q000009:adverse effects
chemical_list: D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D059003:Topoisomerase Inhibitors; D050257:Tubulin Modulators